The U.S. FDA has granted Emergency Use Authorization for Roche (OTMKTS:RHHBY) at-home Covid-19 test, which uses a nasal swab and provides results in as little as 20 minutes.
Covid-19 is providing quite difficult to contain despite the wide availability of vaccines and testing will likely remain key to keeping the broader economy open. For example, the U.S. government intends to start distributing 500 million at-home tests in January. This could potentially drive demand for Covid-19 test kits for companies including Roche.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
|S&P 500 Return||1%||26%||111%|
|Trefis MS Portfolio Return||2%||47%||296%|
 Month-to-date and year-to-date as of 12/27/2021
 Cumulative total returns since 2017